HEALTHCARE PROFESSIONALS

Clinical Data

Vencarm® XL meets all the relevant regulatory requirements of a bioequivalent medicine (Reference product EFEXOR XL® (venlafaxine prolonged-release capsules) (Pfizer Limited, UK)).1 Bioequivalence studies of the 150 mg strengths (Fasting, Fed & Steady state [under fed conditions]) of the Test (venlafaxine XL) and Reference product (EFEXOR XL® (Pfizer Limited, UK)), were carried out comparing the mean plasma concentrations, for both Venlafaxine and the major metabolite, O-Desmethylvenlafaxine. The graphs for Venlafaxine are provided.

Single dose study comparing Vencarm XL 150mg and Efexor XL 150mg under fasted conditions

Single dose study comparing Vencarm XL 150mg and Efexor XL 150mg under fed conditions

Steady State study comparing Vencarm XL 150mg and Efexor XL 150mg under fed conditions

References: 1) Data on file. 1010067149 v 5.0 September 2021.

TRUSTED BRANDS.
DEPENDABLE SUPPLY CHAIN.

For further information please call: 01730 231148,
email: customerservices@aspirepharma.co.uk or visit www.aspirepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Vencarm XL (venlafaxine), please see the abbreviated prescribing information.

Revision reference – Vencarm XL_8_16.02.2022

More products available
in this range:
Click to view their
individual websites